The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ:AZN) to seek a voluntary withdrawal of the drug’s biologics license and plan an exit from the U.S. market. In November 2024, the Cellular, Tissue,…
Continue reading...